Get the Stockscreener App
2.16
3.14%
-0.07
After Hours:
2.21
0.05
+2.31%
Lexicon Pharmaceuticals Inc stock is traded at $2.16, with a volume of 1.62M.
It is down -3.14% in the last 24 hours and up +18.68% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$2.23
Open:
$2.23
24h Volume:
1.62M
Relative Volume:
0.62
Market Cap:
$959.46M
Revenue:
$49.80M
Net Income/Loss:
$-50.34M
P/E Ratio:
-15.56
EPS:
-0.1388
Net Cash Flow:
$-67.85M
1W Performance:
-3.14%
1M Performance:
+18.68%
6M Performance:
+61.19%
1Y Performance:
+227.27%
1-Day Range:
$2.155
$2.29
1-Week Range:
$2.035
$2.29
52-Week Range:
$0.615
$2.53
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
2.16 | 990.56M | 49.80M | -50.34M | -67.85M | -0.1388 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
LXRX Stock Price, Quote & Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
Lexicon anticipates SONATA-HCM enrollment completion by mid-2026 while highlighting $100m Hercules debt facility - MSN
A Look At Lexicon Pharmaceuticals (LXRX) Valuation After Improved Q1 Revenue And Narrowed Net Loss - Sahm
Lexicon Pharmaceuticals: up to 50 percent of type 2 diabetes patients affected by painful neuropathy - Traders Union
Lexicon Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-05-15 - Seeking Alpha
Navigating Life with Hypertrophic Cardiomyopathy - GlobeNewswire Inc.
Lexicon Pharmaceuticals (LXRX) Is Up 52.5% After Q1 Loss Narrows And Revenue JumpsHas The Bull Case Changed? - simplywall.st
Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's Changed - Yahoo Finance
Lexicon Pharmaceuticals management to join Nasdaq HQ fireside chat - Traders Union
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - Herald and News
LXRX Maintained by Citigroup -- Price Target Raised to $3.10 - GuruFocus
$Lexicon Pharmaceuticals (LXRX.US)$ 🚀🚀🚀🚀🚀🤩🤩🤩🤩🤩 - Moomoo
Citigroup Issues Positive Forecast for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price - MarketBeat
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $3.1 - Moomoo
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones - Yahoo Finance
Lexicon Pharmaceuticals (LXRX) reports break-even earnings for Q1 - MSN
[SCHEDULE 13D/A] LEXICON PHARMACEUTICALS, INC. Amended Major Shareholder Report - Stock Titan
Major holder Artal group converts LXRX (LXRX) Series B preferred into 20.4M common shares - Stock Titan
5 Best Fast Growing Penny Stocks to Buy Right Now - Insider Monkey
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
LXRX SEC FilingsLexicon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Q1 2026 Lexicon Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Lexicon Pharmaceuticals: Buy Rating Reiterated as Value Catalysts Build; $6 Price Target Maintained - TipRanks
Lexicon Pharmaceuticals Q1 2026 earnings preview - MSN
Lexicon: Q1 Earnings Snapshot - theheraldreview.com
Lexicon Pharmaceuticals Q1 Earnings Call Highlights - Barchart.com
Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
LXRX Financials: Income Statement, Balance Sheet & Cash Flow | Lexicon Pharmaceuticals Inc - Stock Titan
Lexicon Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Lexicon Pharmaceuticals (NASDAQ: LXRX) Q1 2026 loss narrows on Novo milestones - Stock Titan
Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surge - Investing.com Nigeria
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1 - Yahoo Finance
LEXICON PHARMACEUTICALS ($LXRX) Releases Q1 2026 Earnings - Quiver Quantitative
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates - The Manila Times
Lexicon targets diabetes filing, heart trial, obesity study milestones - Stock Titan
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lexicon (NASDAQ: LXRX) Q1 2026 results, milestones and $100M loan - Stock Titan
$100M Hercules loan backs Lexicon (NASDAQ: LXRX) refi and milestones - Stock Titan
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):